Build status - In Progress

A Phase 3 Randomized Double-Blind Placebo-Controlled Parallel Arm Multicenter Study Evaluating the Efficacy and Safety of Pridopidine in Patients with Early Stage of Huntington Disease

Recruiting
99 years or below
All
1 Location

Brief description of study

PROOF-HD is a placebo-controlled (double blind) multicenter Phase 3 trial of Pridopidine in Huntington Disease patients. Recruitment: 480 participants at 60 sites, a target of 8 participants per site. Procedures include administration of study drug or placebo in tablet form twice daily for a period of 67-80 weeks with option for OLE. Participation requires periodic on-site visits as well as virtual and phone visits. EKG and lab monitoring, physical exam and motor testing, interview tools.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research
  • Age: 99 years or below
  • Gender: All
Updated on 11 Aug 2021. Study ID: 844637

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center